Dignitana AB: Report from Extraordinary Shareholders Meeting on 16 March 2018

Lund, Sweden – 16 March 2018Dignitana AB, world leader in clinically superior scalp cooling technology, today held an extraordinary shareholders meeting at the company´s office in Lund. In all scheduled actions the shareholders acted in accordance with the board´s proposals. Below is a summary of the decisions.  

The shareholders meeting determined that board fees of 100 000 SEK will be paid to Swedish board members. American board members will not be paid for their participation in Dignitana AB Board but will be appointed to Dignitana, Inc. Board and will receive a fee of 12 000 USD for their responsibilities to the Dignitana, Inc Board.  

The shareholders meeting decided that the Board shall consist of four members without deputy board members. William Cronin is reelected as Board Member; Thomas Kelly, Ingrid Atteryd Heiman and Mikael Wahlgren are elected as new Board Members; and Thomas Kelly is elected as Chairman of the Board.

Extraordinary meeting results

Investor Relations                                                       

Melissa Bourestom                                       


00 1 773 387 8504                                         


Media Contact   

Caren Browning  

King + Company

00 1 212 561 7464


About Dignitana AB (publ)
Dignitana is a Swedish public company based in Lund and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on Nasdaq First North Stockholm and has appointed Erik Penser Bank as Certified Adviser. Headquartered in Dallas Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For more information visit www.dignitana.se and www.dignicap.com.

This announcement contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 1520 (CET), 16 March 2018.

About Us

About Dignitana AB (publ)Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. Dignitana AB is listed on Nasdaq First North Stockholm in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Erik Penser Bank is Certified Adviser. Learn more at www.dignitana.se and www.dignicap.com.